Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia

Myopia Clinical Trial

Official title:

A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00762541
• Other study ID #: MEL 80-2006-1
• Status: Completed
• Phase: N/A
• Start date: October 2006
• Est. completion date: July 2009

Study information

• Verified date: July 2018
• Source: Carl Zeiss Meditec, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of moderate to high myopia (nearsightedness), when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.

Description:

LASIK has become one of the most common refractive eye procedures performed in the country. Currently the MEL 80 Excimer Laser System is approved for the elimination of myopia of less than or equal to -7.0 D with or without refractive astigmatism of less than or equal to -3.0 D, with a maximum MRSE of -7.00 D. The goal of this study is to assess the safety and effectiveness information on the treatment of moderate to high magnitudes of myopia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: July 2009
• Est. primary completion date: July 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane, with a maximum MRSE =-12.00 D.

• Stable refraction for at least the last twelve months, as demonstrated by a change of less than 1.00 D of the spherical equivalent during the twelve months prior to the baseline examination of the eye to be treated, documented by previous clinical records.

• Discontinue use of contact lenses at least 2 weeks for hard contacts and 3 days for soft lenses prior to the preoperative examination.

• Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D.

• Visual acuity correctable to at least 20/40 in both eyes.

• UCVA of 20/40 or worse in the operative eye.

• At least 18 years of age.

• Operative eye must be targeted for emmetropia.

• Have a normal corneal topography.

• Willing and able to return for scheduled follow up examinations for twelve months after surgery.

• Sign and be given a copy of the written Informed Consent form.

Exclusion Criteria:

• History of anterior segment pathology, including cataracts (in the operative eye).

• Clinically significant dry eye syndrome unresolved by treatment.

• Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease.

• Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect).

• An ablation deeper than 250 microns from the corneal endothelium.

• Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings.

• Blind in the fellow eye.

• Undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.

• History of ocular Herpes zoster or Herpes simplex keratitis.

• History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP >21 mm Hg.

• Must not have diabetes, diagnosed autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.

• Must not be immunocompromised or use chronic systemic corticosteroid or other immunosuppressive therapy.

• Patients must not be pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.

• Patients must not have a known sensitivity to planned study medications.

• Patients must not be participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.

• For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures

• 1. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap.

• 2. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye.

• 3. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure.

• 4. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target.

• 5. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.

Related Conditions & MeSH terms

• Myopia

Intervention

Device:
• MEL 80 Treatment of High Myopia
The reduction or elimination of myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE = -12.00 D.

Locations

Country	Name	City	State
United States	Fine, Hoffman, and Packer	Eugene	Oregon
United States	Dishler Laser Institute	Greenwood Village	Colorado
United States	Discover Vision Centers	Kansas City	Missouri
United States	Davis Duehr Dean Eye Clinic	Madison	Wisconsin
United States	US Navy Refractive Surgery Center	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Carl Zeiss Meditec, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	At the point of stability, for myopes > 7 D spherical equivalent (SE), a minimum of 30% should have an achieved refraction within ± 0.50 D of the intended outcome, and 60% should have an achieved refraction within ± 1.00 D of the intended outcome.		Point of stability
Primary	For myopes > 7 D spherical equivalent (SE), a minimum of 75% of eyes should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established.		Point of stability
Primary	95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D.		Point of stability
Primary	Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1% of eyes that had a BSCVA of 20/20 or better before surgery.		Point of stability
Primary	Loss of more than 2 lines of BSCVA should occur in less than 5% of eyes		Point of stability
Primary	Less than 5% of eyes treated for sphere only should have a magnitude of postoperative manifest refractive astigmatism that varies from baseline cylinder by greater than 2.00 D at the postoperative interval at which stability has been established.		Point of stability
Primary	Incidence of Adverse Events to occur in less than 1% of eyes		Postopertive visits
Secondary	Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable.		Postoperative visits 3, 6, 9 and 12 months
Secondary	Incidence of Complications		Postoperative visits
Secondary	Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable		Preoperative and Postoperative visits 3, 6, 9 and 12 months